Skip to main content

Bioventus Inc.

BVS
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001665988

No open-market purchases or sales by Bioventus Inc. insiders were filed in the last 90 days; 156 institutions reported holding it in 13F filings for Q2 2026, worth $509.4M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Bioventus Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Bioventus Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Bioventus Inc.
NameTitleLast reported holdingLast filingFilings, past year
Sutter Martin PDirector, 10% Owner117,523Jun 4, 20261
Hawkins William ADirector297,640Jun 4, 20261
Nohra Guy PDirector148,892Jun 4, 20262
Stalnecker Susan MDirector138,239Jun 4, 20261
Neels Guido JDirector117,523Jun 4, 20261
Bartholdson John A.Director, 10% Owner111,902Jun 4, 20261
Beyer PatDirector108,718Jun 4, 20261
Cowdy Philip G.Director43,982Jun 4, 20263
Ladone Mary KayDirector111,263Jun 4, 20261
McMurry-Heath MichelleDirector77,279Jun 4, 20263
Church Katrina JSVP & Chief Compliance Officer64,164Apr 14, 20263
D'Adamio AnthonySVP & General Counsel153,655Apr 14, 20263
Singleton Mark LeonardSVP & CFO177,333Apr 14, 20264
Claypoole Robert EPresident and CEO135,944Mar 17, 20262
Bihl Anthony P IIIInterim CEO26,595IndirectAug 22, 20230
Michas Alexis P10% Owner6,833,857IndirectAug 15, 20230
Juniper Investment Company, LLC10% Owner6,833,857IndirectAug 15, 20230
Reali Kenneth MichaelFmr. CEO and Director30,085Apr 21, 20230
Pavesio AlessandraFmr. SVP & Chief Science Off.148,309Apr 21, 20230
Nosenzo JohnFmr. Chief Commercial Officer87,148Apr 21, 20230
Vizirgianakis Stavros G.Director2,781,888Jun 22, 20220
Anglum Gregory O.SVP & CFO55,013Feb 15, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 15, 2025 (view filing)Apr 114 daysD'Adamio AnthonySVP & General CounselSSaleClass A Common Stock−2.96K$7.57−$22.4K−2.2%131.4K after10b5-1
Apr 15, 2025 (view filing)Apr 114 daysSingleton Mark LeonardSVP & CFOSSaleClass A Common Stock−3.88K$7.57−$29.3K−2.7%141.1K after10b5-1
Nov 10, 2025 (view filing)Nov 73 daysMcMurry-Heath MichelleDirectorSSaleClass A Common Stock−17.7K$7.42−$131.3K−23.7%57.0K after
Dec 8, 2025 (view filing)Dec 44 daysNohra Guy PDirectorSSaleClass A Common Stock−10.0K$7.57−$75.7K−7.9%116.6K after
Mar 13, 2026 (view filing)Mar 112 daysMcMurry-Heath MichelleDirectorSSaleClass A Common Stock−12.0K$8.79−$105.5K−21.1%45.0K after